Other Events ·
Court of Milan denies minority shareholders' request to suspend Genenta's capital increase tied to ATC acquisition
GNTAGenenta Science S.p.A.
The Court of Milan denied an application for interim relief brought by certain minority shareholders challenging the capital increase approved by Genenta Science S.p.A.'s Board of Directors on May 18, 2026. This capital increase was conducted in connection with the Company's acquisition of A.T.C. S.r.l. (ATC). As a result, the capital increase and the issuance of shares related to the ATC acquisition remain effective pending proceedings on the merits. The Court concluded that plaintiffs did not establish unequivocal elements of unlawfulness sufficient to warrant suspension. The underlying civil action remains pending. Genenta Science S.p.A. operates in the biotechnology sector, focusing on the development of therapies for rare diseases.